Literature DB >> 15679540

Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia.

Tiao-Lai Huang1.   

Abstract

The uses of lorazepam and electroconvulsive therapy (ECT) have been proven to be effective in treating catatonia. In the present study a modified treatment strategy (i.e. lorazepam i.m. injection or diazepam infused i.v. if lorazepam failed, not with ECT) was proposed to rapidly relieve catatonic signs in patients with schizophrenia. During a 3-year period, 14 patients with catatonic schizophrenia in Chinese ethnic background Taiwanese were brought to the emergency unit of a general hospital. First, the patients were immediately treated with lorazepam 1 or 2 ampules (2 mg/mL per ampule) i.m. injection (IMI) during 2 h. Second, if the previous 2 ampules of lorazepam IMI failed, diazepam infused i.v. (10 mg/2 mL per ampule) in normal saline 500 mL every 8 h would be done during 1 day. The response rate of catatonic signs in these 14 patients with lorazepam IMI during the first 2 h was 85.7% (12/14). However, according to the results of this method, the total response rate to benzodiazepines during 1 day was 100%(14/14). These results suggested that this modified treatment strategy could rapidly and completely relieve catatonic signs, even without the use of ECT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15679540     DOI: 10.1111/j.1440-1819.2005.01331.x

Source DB:  PubMed          Journal:  Psychiatry Clin Neurosci        ISSN: 1323-1316            Impact factor:   5.188


  9 in total

1.  An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?

Authors:  Ramadhan Oruch; Anders Lund; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2010-01-27

2.  In thrombin stimulated human platelets Citalopram, Promethazine, Risperidone, and Ziprasidone, but not Diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner.

Authors:  Ramadhan Oruch; Erlend Hodneland; Ian F Pryme; Holm Holmsen
Journal:  J Chem Biol       Date:  2009-04-30

3.  Response rate of catatonia to electroconvulsive therapy and its clinical correlates.

Authors:  Dhanya Raveendranathan; Janardhanan C Narayanaswamy; Senthil V Reddi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-12-30       Impact factor: 5.270

Review 4.  Delirious mania and malignant catatonia: a report of 3 cases and review.

Authors:  Mark B Detweiler; Abhishek Mehra; Thomas Rowell; Kye Y Kim; Geoffrey Bader
Journal:  Psychiatr Q       Date:  2009-02-06

Review 5.  A clinical review of the treatment of catatonia.

Authors:  Pascal Sienaert; Dirk M Dhossche; Davy Vancampfort; Marc De Hert; Gábor Gazdag
Journal:  Front Psychiatry       Date:  2014-12-09       Impact factor: 4.157

6.  Successful treatment of treatment-resistant schizophrenia in a 10-year-catatonic patient by augmentation of selective serotonin reuptake inhibitors: a case report.

Authors:  Mei-Jung Chen; Shiau-Shian Huang; Kai-Dih Juang; Chin-Hong Chan
Journal:  Medicine (Baltimore)       Date:  2015-05       Impact factor: 1.889

7.  The Lorazepam and Diazepam Protocol for Catatonia Due to General Medical Condition and Substance in Liaison Psychiatry.

Authors:  Chin-Chuen Lin; Yi-Yung Hung; Meng-Chang Tsai; Tiao-Lai Huang
Journal:  PLoS One       Date:  2017-01-23       Impact factor: 3.240

8.  Periodic catatonia with long-term treatment: a case report.

Authors:  Ruei-An Chen; Tiao-Lai Huang
Journal:  BMC Psychiatry       Date:  2017-09-29       Impact factor: 3.630

9.  Increased serum anti-N-methyl-D-aspartate receptor antibody immunofluorescence in psychiatric patients with past catatonia.

Authors:  Chin-Chuen Lin; Yi-Yung Hung; Meng-Chang Tsai; Tiao-Lai Huang
Journal:  PLoS One       Date:  2017-10-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.